HR 174 Louisiana House · 2026 Regular Session

DRUGS/TESTING: Requests the state surgeon general and the Louisiana Department of Health to assess the feasibility of advancing fenbendazole or similar treatments for potential human use in cancer treatment and to provide guidance on engaging federal authorities for expedited evaluation while protecting public health

This Louisiana legislative resolution directs the state Surgeon General and the Department of Health to evaluate whether fenbendazole or similar drugs could be used to treat cancer. The bill asks these health officials to determine if it is feasible to move such treatments toward human use and to seek guidance from federal agencies for a faster review process. All proposed actions must include safeguards to ensure public health remains protected during any potential advancement of these therapies. The measure focuses specifically on assessing the scientific viability and regulatory pathways for these substances rather than mandating their immediate adoption.
Bill status passed 3 of 5 stages cleared
Introduction
Apr 2026
Committee Review
May 2026
House Passage
May 2026
Senate Passage
Governor
Introduced Apr 20, 2026 Last action May 21, 2026
Maddy AI version diff · 2 comparisons

What changed between versions

HR174 Engrossed HR174 Enrolled · 4 edits · May 19, 2026
MODERATE
The bill was finalized for official enactment, changing the header from 'Engrossed' to 'Enrolled' and updating the page count. The most significant policy change is the expansion of the request to include 'similar potential treatments' alongside fenbendazole, broadening the scope beyond just this specific drug. The list of sponsoring representatives was also updated to include four additional members.
Scope change
The bill's scope was broadened to apply to fenbendazole and similar potential cancer treatments, rather than being limited strictly to fenbendazole.
SCOPE

The request for assessment was expanded to include 'fenbendazole or similar potential treatments' instead of only fenbendazole.

The request for federal engagement was similarly expanded to cover 'fenbendazole or similar treatments'.

REQUIREMENT

The list of sponsoring representatives was updated to include Amedee, Berauld, Wilford Carter, Carver, Horton, Schamerhorn, and Taylor.

TECHNICAL

The document status changed from 'Engrossed' to 'Enrolled' and the page count was adjusted from 3 pages to 2 pages.

Floor votes · House May 18, 2026

How they voted

870
Passed · 18 other
Total votes 105
May 18, 2026
D Democratic33
21 Yea 12
63% Yea
R Republican72
66 Yea 6
91% Yea
Vote distribution
All Yea All Nay Mixed No data
Full legislative history

Actions timeline

Total actions
8
Key actions
2
Committee
2
May 18, 2026
Lower · Passed
Read by title, amended, roll called, yeas 86, nays 0. The resolution was adopted.
lower
May 12, 2026
Lower · Passed
Reported favorably (10-0).
lower
Apr 21, 2026
Committee
Read by title, under the rules, referred to the Committee on Health and Welfare.
lower
1 primary · 8 co-sponsors

Sponsors